Abstract: A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy is said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition.

Abstract: A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition.

Abstract: A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ?-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ?-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another additive selected from the group consisting of L-lysine, L-arginine, L-ornithine (or its pharmaceutically acceptable salts; e.g., L-ornithine hydrochloride), ?-aminobutyric acid, 5-aminovaleric acid, 7-aminoheptanoic acid, glycylglycine, triglycine, N-?-acetyl-L-arginine, betaine, sarcosine, gelatin, HSA, streptokinase, tPA, uPA, non-ionic surfactants, glycerin, D-sorbitol, combinations thereof, and mixtures thereof. A method for prolonging the activity of an autodegradable enzyme comprises storing the enzyme after manufacture at a low pH, and reconstituting the acidified enzyme before use with a solution containing at least one of such additives.

Abstract: The invention is in the field of using a computer to provide automated investment allocation advice, selection of investment securities, customization of the automated advice, execution of investment securities, maintenance/monitoring of investment portfolios and rebalancing of investment portfolios. A user is connected to the Internet. The user connects to the portfolio management program (PMP) host computer through the Internet. The user completes a questionnaire that the PMP uses to generate a suitable investment allocation and specific portfolio strategy recommendation. The user reviews the strategy and specific information about the strategy. The information is transmitted across the Internet to the user. The information transmitted includes historic and/or hypothetical performance, historical and/or hypothetical holdings, current securities selections of the strategy, and a description of the strategy's selection methodology.

Abstract: A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition.

Abstract: A method of lowering intraocular pressure and/or treating glaucoma comprises administering to a patient a therapeutically effective amount of a fused pyrrolocarbazole derivative, or a pharmaceutically acceptable salt or prodrug thereof.

Abstract: A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition.

Abstract: The invention provides the use of a radiation source which is a low energy X-ray emitter, e.g. with an energy of emission of the principal photon in the range of 20 to 100 keV, preferably 20 to 40 keV and with a half life of 10 to 100 days, preferably 15 to 70 days, for the treatment of restenosis. Suitable radioisotopes include palladium-103, dysprosium-159, samarium-145, cadmium-109, ytterbium-169 and preferably iodine-125. High activity radioactive bodies and sources comprising such radioisotopes, and methods for the manufacture of such sources, are also disclosed.

Abstract: A system for transmitting and receiving signals includes an array system of one or more active electronically scanned arrays. The array system includes a receive portion of a first number of receive elements and a transmit-receive portion of a second number of transmit-receive elements. A transmit-receive element includes monolithic microwave integrated circuit power amplifiers and low-loss miniature combiners. A signal processing system processes signals. A beam forming system generates receive beams of the receive elements. A receive beam has a receive beam beamwidth that is less than a transmit beam beamwidth of a transmit beam of the transmit-receive elements.

Abstract: The invention provides a method of embolus therapy comprising administering into the vasculature of a perfused zone of tissue in a human or non-human animal subject a composition comprising particles of a size or formulation selected to generate emboli at a target site within said subject, characterised in that as said particles are used solid water-insoluble particles of a non-radioactive diagnostically effective compound or vesicles encapsulating a non-radioactive diagnostically effective compound or a solution thereof, and in that embolus location is detected by a diagnostic imaging technique.

Abstract: According to one embodiment of the invention a method for controlling cooling of a heat-generating structure disposed in an environment having an ambient pressure includes providing a fluid coolant and reducing the pressure of the coolant to a subambient pressure at which the coolant has a boiling temperature less than a temperature of the heat-generating structure. The method further includes boiling and vaporizing coolant to absorb heat from the heat-generating structure by bringing the coolant into thermal communication with the heat generating structure. The method also includes measuring a parameter indicative of a pressure of the coolant and adjusting the pressure of the coolant in response to control the cooling of the heat-generating structure.

Abstract: Radioactive sources, preferably radioactive seeds, for use in brachytherapy comprising a radioisotope within a sealed biocompatible container, wherein at least one part of a surface of the container is roughened, shaped or otherwise treated so that it is no longer smooth. The surface treatment may enhance the ultrasound visibility of the source and/or reduce the tendency of the source to migrate once implanted in a patient's body. Preferred radioisotopes are palladium-103 and iodine-125.

Abstract: Radioactive sources, preferably radioactive seeds, for use in brachytherapy comprising a radioisotope within a sealed biocompatible container, wherein at least one part of a surface of the container is roughened, shaped or otherwise treated so that it is no longer smooth. The surface treatment may enhance the ultrasound visibility of the source and/or reduce the tendency of the source to migrate once implanted in a patient's body. Preferred radioisotopes are palladium-103 and iodine-125.

Abstract: A method for the immobilization of a radioactive anion on the surface of a metal substrate, said method comprising treating the substrate with an oxidizing agent in the presence of a solution of a radioactive anion which forms an insoluble salt with ions of said metal. Preferably, a binding agent will also be present. Preferably, the metal is silver, the radioactive anion is 125I− and the binding agent comprises bromide ions.